DGAP-News: CureVac
/ Key word(s): Alliance/Agreement
CureVac : CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
07.01.2021 / 08:30
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
- Companies enter into a collaboration and services agreement
- Bayer to support CureVac in numerous areas, including development and supply of CVnCoV
- CureVac benefits from Bayer's expertise and established infrastructure
- Plan to facilitate the supply of several hundred million doses
Berlin and Tübingen, Germany/ Boston, USA, January 7, 2021 -
Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac's COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries.